20th Annual New York Lung Cancers Symposium®

20th Annual New York Lung Cancers Symposium® is organized by Physicians' Education Resource, LLC (PER) and will be held on Nov 15, 2025 in New York City, New York, United States of America.

Description:
At the New York Lung Cancers Symposium® attendees will experience a comprehensive overview of multidisciplinary lung cancer treatment. Now in it’s 20th year, this meeting is designed to increase your knowledge of lung cancer therapy, including the roles that surgery, radiology, pulmonology, and pathology play to ensure the most accurate diagnosis of lung cancers. You will hear thought leaders from the New York area discuss optimal approaches for early-stage and locally advanced disease, as well as present the latest data on immunotherapy and targeted agents in metastatic lung cancers. These multidisciplinary interactions will be illustrated in a tumor board format, which will also allow participants to present questions and clinical challenges from their practice.

The ever-popular interactive case challenges will provide you with an opportunity to discuss the application of clinical data for real-world patient cases. A special session has been designed for nurse practitioners and physician assistants, to provide a tailored experience for learning and networking.

Learning Objectives:

• Examine biomarkers and testing strategies to optimize and inform clinical decision-making for the management of patients with lung cancers
• Analyze recent clinical trial evidence supporting therapeutic advancements in the management of early-stage and metastatic lung cancers
• Devise strategies to integrate monotherapy and combination immunotherapeutic approaches in the management of patients with thoracic malignancies
• Apply diverse therapeutic strategies across multiple lines of therapy for patients with lung cancer considering both oncogene-driven subtypes and those lacking actionable mutations
• Determine individualized strategies for sequencing therapy utilizing clinical trial evidence, performance status, and tumor characteristics
• Integrate methods to mitigate and manage treatment-related toxicities in patients with lung cancers